AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05586997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonded-Hyrax
Description: The expansion screw of the bonded-hyrax will be activated until the palatal cusps of the permanent maxillary first molars are opposing the buccal cusps of the permanent mandibular first molars
Study NCT05586997 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bonded Rapid Maxillary Expansion and low-Level Laser therapy
Description: Ten sessions of 0.5 watts for 20 seconds at 4 points along the mid-palatal suture
Study NCT02038179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Participants who received allopurinol as urate lowering therapy, at a daily dose of 300 mg once daily by mouth for a 4 week duration.
Study NCT02038179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants who received placebo tablet (matching Allopurinol 300 mg) daily by mouth for a 4 week duration.
Study NCT04351165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297
Description: IMP4297 10mg/capsule; IMP4297 20mg/capsule;
Study NCT04078711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Losartan 100Mg Tab
Description: 100Mg Tab, qd, po, 6 months
Study NCT04078711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 100Mg Tab
Description: 100Mg Tab, qd, po, 6 months
Study NCT04078711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qianyangyuyin 20g Granule
Description: 20g, Granule, bid, po, 6 months
Study NCT04078711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Similar granule manufactured to mimic qianyangyuyin granule, 20g, Granule, bid, po, 6 months
Study NCT04835727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-vegetarian diet and increase fiber consumption
Description: All patients in this study will be advised by an experienced nutritionist to intake high fiber diets with a low intake of red meat and processed food.
Study NCT00953888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: Single dose of oral solution.
Study NCT00953888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of oral solution.
Study NCT05046015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10% Urea foot lotion
Description: During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 Lipolotion 10% Urea once daily in the evening by themselves.
Study NCT05046015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10% Urea foot ointment
Description: During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 ointment10% Urea once daily in the evening by themselves.
Study NCT00149396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NV1020
Description: NV1020 dose levels: 3x10\^6, 1x10\^7, 3x10\^7, and 1x10\^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks
Study NCT04297605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg
Study NCT02764502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure Gauge Manometer
Description: Identification of epidural space
Study NCT03086629 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient Concerns Inventory
Study NCT03086629 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Patient Concerns Inventory
Study NCT02236312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Study NCT02236312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03069534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhIL-2
Description: RhIL-2 treatment intervention was consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotharapy. rhIL-2 (500,000 U/m)regimen was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7.
Study NCT01366313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: initial doses was 1.5g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
Study NCT01366313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Initial of morphine was 5mg, with dose adjustment intervals 1 mg .
Study NCT01366313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol- Morphine
Description: The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
Study NCT04998890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adventure-based cognitive behavioral intervention
Description: The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course entailed Improving Mental Health for University Success in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues.
Study NCT03675360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet
Description: Behavioral modification to reduce carbohydrate consumption. Target \<40 g net carbohydrates per day for first 3 months; \<60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations.
Study NCT02517957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furoic acid loperamide hydrochloride cream
Description: Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied.
Study NCT02517957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furoic acid loperamide hydrochloride cream
Description: Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied.
Study NCT02517957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mullite ointment
Description: Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
Study NCT02517957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mullite ointment
Description: Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
Study NCT02517957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% boric acid solution
Description: 3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
Study NCT02517957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% boric acid solution
Description: 3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
Study NCT02517957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zine oxide
Description: In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
Study NCT02517957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zine oxide
Description: In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
Study NCT03746925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Anterior Approach (DAA)
Description: Direct Anterior Approach surgery to replace the hip.
Study NCT04297605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Chemotherapy)
Description: 500 mg/m2 day 1 of 21 day cycle (for non-squamous only)
Study NCT04297605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (Chemotherapy)
Description: 100 mg/m2 days 1,8 of 21 day cycle x 4 cycles
Study NCT01225380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9190
Description: GS-9190 capsule, 20 mg BID, 16 or 24 weeks
Study NCT01225380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9256
Description: GS-9256 capsule, 150 mg BID, 16 or 24 weeks
Study NCT01225380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegasys®
Description: peginterferon alfa-2a, (solution for injection) 180 µg/week, up to 48 weeks
Study NCT01225380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus®
Description: ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), up to 48 weeks
Study NCT01225380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9190 placebo
Description: placebo matching GS-9190 capsule BID, 24 weeks
Study NCT01225380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9256
Description: GS-9256 capsule, 150 mg BID, 24 weeks
Study NCT01225380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegasys®
Description: peginterferon alfa-2a (solution for injection) 180 µg/week, up to 48 weeks
Study NCT03746925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SuperPATH
Description: SuperPATH approach surgery to replace the hip.
Study NCT05203601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIBP-03
Description: Stage 1:~Six dose groups of 2, 5, 10, 15, 20 and 40 mg/kg were planned. Dose increments began at 2 mg/kg using accelerated titration. In the first dose group, after the first patient was injected with Sibp-03, if the subject developed toxicity grade ≥2（CTCAE v5.0 standard）within 21 days of initial administration，then the subject increased to 3 and the study design method in this dose level convert to 3+3. If the subject didn't develop toxicity grade ≥2, then the study of the second and next dose group can be carried out using 3+3 incremental design.~Stage 2:~Cohort 1 included patients with advanced head and neck squamous cell carcinoma and cohort 2 included patients with breast cancer. According to the results of dose escalation stage and similar drug trials, 5mg/kg and 10mg/kg dose levels were selected to enter this phase. Each cohort will be extended to include 6-8 subjects to receive this product in combination with the standard treatment study.
Study NCT03961763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA+DHA
Description: 4 g/day EPA+DHA in tablets of 1g, 4 tablets daily, over 8 weeks (56 days)
Study NCT03961763 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 g/day olive oil placebo in tablets of 1g, 4 tablets daily, over 8 weeks (56 days).
Study NCT04687410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProControl, MediGlobe
Description: standard 22G FNA needle
Study NCT04687410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TopGain, Medi-Globe
Description: novel 22G crown-cut FNB needle
Study NCT04187443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: MS-553
Study NCT03860298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviFUS System
Description: Using NaviFUS System treatment for 10 minutes in drug resistant epilepsy. The site of the NaviFUS exposure is where the future surgery will be removed. Patients will concomitant use of anti-epileptic drugs (AEDs).
Study NCT00889655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely (polyethylene glycol)
Description: 4 L of golytely, in split dosing. If the patient has a morning colonoscopy, they will take 2 L of golytely over 2 hours the morning prior to their procedure and repeat this at 6 pm the night prior to their procedure.
Study NCT00889655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MiraLax (polyethylene glycol 3350)
Description: 238 gm of MiraLax mixed in 64 oz of Gatorade, to be consumed in split dosing the day prior to scheduled colonoscopy.
Study NCT01406119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-806
Description: ABT-806 will be administered by intravenous infusion.
Study NCT02689804 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LNG-EC
Description: FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg
Study NCT02689804 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: UPA-EC
Description: FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg
Study NCT01954238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GCC-4401C
Description: * Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.~* The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.~* GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.~* The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.~* In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion.
Study NCT01954238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GCC-4401C
Description: * Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.~* The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.~* GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.~* The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.~* In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion.
Study NCT01954238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban (Xarelto®) 20 mg tablets for oral administration IMP, placebo and comparator will be administered the same time points. The comparator will be administered open-label 30 minutes after a standard breakfast.
Study NCT01954238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GCC-4401C matching placebo(Capsule): Strength is not applicable. GCC-4401C and placebo will be administered double-blind after a 10 hours fast.
Study NCT02992028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Nutrition (Vitamins) injection
Study NCT02992028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Saline injection
Study NCT02565316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepeta menthoides Boiss & Bohse freeze dried extract
Study NCT02565316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Study NCT01225380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-9190 placebo
Description: placebo matching GS-9190 capsule BID, 24 weeks
Study NCT01225380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-9256 placebo
Description: placebo matching GS-9256 capsule BID, 24 weeks
Study NCT01225380 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pegasys®
Description: peginterferon alfa-2a (solution for injection) 180 µg/week, 48 weeks
Study NCT01225380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Copegus®
Description: ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), 48 weeks
Study NCT03931746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Porcine xenograft
Description: The EZ-DERM™ porcine xenograft is a biosynthetic dressing made from porcine collagen containing aldehyde crosslinking. It has been most commonly applied to the management of 2nd degree burns, both partial-thickness and full-thickness defects. This dressing can be used for two healing purposes, either for primary healing or as an intermediate in the preparation for a skin graft
Study NCT03557645 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Baseline Mechanical Ventilation
Description: The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV).
Study NCT03557645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VHI With Inspiratory Pause
Description: Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory pause.
Study NCT02078193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Patients will be converted from their MMF to Belatacept
Study NCT00299819 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-545
Description: 0.3 mg/kg IV (n=6) at Study Day 0
Study NCT00299819 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI 545
Description: 0.3 mg/kg IV (n=6) at Study Day 0
Study NCT02346877 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized Patient Counselling
Description: In the interventional cohort participants enrolled on the study will receive personalized patient counselling using the IMS-model based on the baseline BMQ results through a patient assistance program for patients on Enbrel (Etanercept) therapy.
Study NCT04256980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib will be self-administered at 9mg Or 13.5mg as a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule
Study NCT01688323 — intervention group
Intervention type: OTHER
Intervention: Collect Blood and Survey Instruments
Description: Each subject will be administered the appropriate surveys and blood draws over the course of the study.
Study NCT01945944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (3%)
Description: 3mL of HTS given via nebulizer every 6hrs
Study NCT01945944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% saline)
Description: 3mL of normal saline given via nebulizer every 6hrs
Study NCT03557645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VHI Without Inspiratory Pause
Description: Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) without an inspiratory pause.
Study NCT01442922 — intervention group
Intervention type: OTHER
Intervention: completion of the (VAS) for level of back pain
Description: Patients will complete the (VAS) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
Study NCT01442922 — intervention group
Intervention type: OTHER
Intervention: completion of the (OLBPQ) for assessment of function
Description: Patients will complete the (OLBPQ) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
Study NCT02949947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: 15 mg/kg by vein (up to 750 mg) over 15 min infusion. Dose repeated 1 week later.
Study NCT02949947 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplements
Description: Participants take iron supplements by mouth every day for up to 3 months.
Study NCT02949947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
Study NCT02949947 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
Study NCT03708445 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cytology staining
Description: Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~1. conventional cytology staining method~2. new cytology staining method using antibody of aminoacyl-tRNA synthetases
Study NCT03576638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Accordion Pill Carbidopa/Levodopa
Description: AP 50/500 TID days 2-7
Study NCT03576638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet CR 25Mg-100Mg Extended-Release Tablet
Description: 25/100 1.5 pills five times/day
Study NCT01431339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Dalbavancin
Description: IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8